Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

MPS IIIB (Sanfilippo B Syndrome) Clinical Trial

Official title:

A Prospective Cross-Sectional and Longitudinal Study With Additional Retrospective Chart Review to Evaluate Clinical and Biochemical Characteristics and Disease Progression in Patients With Mucopolysaccharidosis Type IIIB

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02293408
• Other study ID #: NGLU-NH02
• Status: Terminated
• Start date: September 14, 2014
• Est. completion date: July 11, 2017

Study information

• Verified date: September 2018
• Source: Alexion Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of this study are to describe the clinical and biochemical characteristics and course of disease progression in participants with Mucopolysaccharidosis type IIIB (MPS IIIB)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: July 11, 2017
• Est. primary completion date: July 11, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

A participant must meet all of the following inclusion criteria to be eligible for this study:

1. The participant has a definitive diagnosis of MPS IIIB, as determined by either of the following:

1. Documented deficiency in alpha-N-acetyl-glucosaminidase (NAGLU) enzyme activity or

2. Documented functionally-relevant mutations in both alleles of the NAGLU gene.

2. The participant is at least 1 year of age (biological age).

3. The participant or the participant's parent provides informed consent.

4. The participant is willing and able to comply with protocol requirements to the extent that may be expected of a participant with cognitive impairment.

In addition to the eligibility criteria above, a participant must meet all of the following criteria for Component 2:

1. The participant meets criterion a or criterion b below.

a. The participant is considered to be at risk of rapid disease progression based on at least 1 of the following criteria:

i. The participant has documented mutations of the NAGLU gene that are reported to be linked to rapid disease progression (for example, disease onset before 6 years of age), or

ii. The participant has a sibling, or other first- or second-degree relative with rapidly progressing MPS IIIB (for example, disease onset before 6 years of age).

b. The participant had disease onset prior to 6 years of age (biological age), as defined by:

i. Cognitive delay evaluated by Bayley Scales of Infant Development, Third Edition (BSID-III) or Kaufman Assessment Battery for Children, Second Edition (KABC-II), or

ii. Language delay, plateauing, or regression of language skills as determined by the Investigator (for example, participant uses isolated words, associated words such as 2-word combinations, sentences, poor or reduced language, and/or difficult to understand).

2. The participant has an age equivalent of =1 year on the Vineland Adaptive Behavior Scales, Second Edition (Vineland II).

Exclusion Criteria:

A participant who meets any of the following exclusion criteria will be ineligible for this study:

1. The participant has visual or hearing impairments sufficient to preclude cooperation with neurodevelopmental testing.

2. The participant has a history of poorly-controlled seizure disorder.

3. The participant is currently receiving medication, which, in the Investigator's opinion, would be likely to substantially confound interpretation of the results (for example, the participant has been on the current dose of psychotropic medication for less than 3 months).

4. The participant is receiving a newly increased dose of melatonin (for example, less than 3 months on current dose).

5. The participant has previously received an investigational therapy for MPS IIIB (with the exception of high dose Genistein >150 milligram/kilogram (mg/kg)/day, which will require a minimum of 3 months wash-out before entering the study) or has had hematopoietic stem cell transplant (HSCT).

6. The participant has any other prior or ongoing medical condition that may present a safety risk, interfere with study compliance, or confound data interpretation.

Related Conditions & MeSH terms

• Disease Progression
• MPS IIIB (Sanfilippo B Syndrome)
• Mucopolysaccharidoses
• Mucopolysaccharidosis III

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alexion Pharmaceuticals

Countries where clinical trial is conducted

United States,  Brazil,  Italy,  Portugal,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collection And Analysis Of Clinical Characteristics Of MPS IIIB	Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.	Baseline to Week 43
Primary	Longitudinal Analysis Of The Course Of Disease Progression In Participants With MPS IIIB	Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).	Baseline to Week 43